Literature DB >> 11052816

In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex.

H Liu1, R A Prayson, M L Estes, J A Drazba, G H Barnett, W Bingaman, J Liu, B S Jacobs, B P Barna.   

Abstract

We reported previously that non-neoplastic astrocytes (derived from brain tissues of patients with epilepsy) expressed interleukin 4 receptor alpha (IL-4Ralpha) and responded to interleukin 4 (IL-4) in culture. To determine whether reactivity of cultured astrocytes was relevant to primary tissue, we investigated IL-4Ralpha expression in specimens of non-neoplastic cerebral cortex removed for surgical treatment of intractable epilepsy compared to specimens of glial tumours, which have been reported to contain IL-4Ralpha. Freshly frozen tissues from eight cases (four epilepsy, four malignant astrocytoma) were evaluated for IL-4Ralpha expression by reverse-transcriptase polymerase chain reaction (RT-PCR), Southern blotting, and double-labelled immunohistochemistry with antibodies to IL-4Ralpha and glial fibrillary acidic protein (GFAP). IL-4Ralpha mRNA was detectable in both non-neoplastic and neoplastic tissues, whereas interleukin 2 receptor gamma chain (IL-2Rgammac) mRNA was not found. By immunohistochemistry, IL-4Ralpha protein co-localized to cells displaying GFAP and astrocytic morphology in epilepsy tissues. As anticipated, IL-4Ralpha was detectable in astrocytoma, but, surprisingly, was also observed in GFAP-positive, non-neoplastic "reactive" astrocytes adjacent to tumour. Results are consistent with the concept that non-neoplastic epilepsy astrocytes express IL-4Ralpha in situ, thus confirming in vitro studies and implying IL-4 sensitivity in vivo. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052816     DOI: 10.1006/cyto.2000.0773

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  15 in total

1.  Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.

Authors:  Marianela Candolfi; Weidong Xiong; Kader Yagiz; Chunyan Liu; A K M G Muhammad; Mariana Puntel; David Foulad; Ali Zadmehr; Gabrielle E Ahlzadeh; Kurt M Kroeger; Matthew Tesarfreund; Sharon Lee; Waldemar Debinski; Dhruv Sareen; Clive N Svendsen; Ron Rodriguez; Pedro R Lowenstein; Maria G Castro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

2.  Commentary: IL-4 and IL-13 receptors and signaling.

Authors:  Sarah M McCormick; Nicola M Heller
Journal:  Cytokine       Date:  2015-07-14       Impact factor: 3.861

Review 3.  Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.

Authors:  Marianela Candolfi; Kurt M Kroeger; Weidong Xiong; Chunyan Liu; Mariana Puntel; Kader Yagiz; Akm Ghulam Muhammad; Yohei Mineharu; David Foulad; Mia Wibowo; Hikmat Assi; Gregory J Baker; Pedro R Lowenstein; Maria G Castro
Journal:  Anticancer Agents Med Chem       Date:  2011-10       Impact factor: 2.505

4.  Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.

Authors:  Linda C Hsi; Suman Kundu; Juan Palomo; Bo Xu; Ryan Ficco; Michael A Vogelbaum; Martha K Cathcart
Journal:  Mol Cancer Ther       Date:  2011-05-19       Impact factor: 6.261

Review 5.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

Review 6.  Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.

Authors:  Bart Thaci; Christine E Brown; Emanuela Binello; Katherine Werbaneth; Prakash Sampath; Sadhak Sengupta
Journal:  Neuro Oncol       Date:  2014-04-10       Impact factor: 12.300

Review 7.  Immunotoxin therapy for CNS tumor.

Authors:  Edward Rustamzadeh; Walter C Low; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

8.  Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma.

Authors:  Friedrich Weber; Anthony Asher; Richard Bucholz; Mitchel Berger; Michael Prados; Susan Chang; Jeffrey Bruce; Walter Hall; Nikolai G Rainov; Manfred Westphal; Ronald E Warnick; Robert W Rand; Frank Floeth; Frank Rommel; Henry Pan; Vijay N Hingorani; Raj K Puri
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

Review 9.  IL-4 in the brain: a cytokine to remember.

Authors:  Sachin P Gadani; James C Cronk; Geoffrey T Norris; Jonathan Kipnis
Journal:  J Immunol       Date:  2012-11-01       Impact factor: 5.422

Review 10.  Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

Authors:  Mariko Kawakami; Koji Kawakami; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.